On Thursday, AtriCure got a positive adjustment to its Relative Strength (RS) Rating, from 66 to 89.
IBD's proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
While the stock is not near a proper buy zone right now, see if it is able to form and break out of a proper chart pattern.
The company reported 0% EPS growth in the latest quarterly report, while sales growth came in at 18%.
AtriCure holds the No. 15 rank among its peers in the Medical-Systems/Equipment industry group. Intuitive Surgical, Electromed and iRadimed are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
